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Abstract 
Purpose of review: The current review summarizes and discusses current research on 
differences elicited between sugars and non-nutritive sweeteners via sugar sensing pathways.  
Recent findings: Sugars, sweeteners and sweetening agents are all perceived as sweet tasting 
due to their ability to bind to the type 1 taste receptor (T1R) family of sweet taste receptors in 
the oral cavity. The ability of a wide variety of chemical ligands to activate the sweet taste 
receptor highlights the importance of sweet-tasting foods during human evolution. The sweet 
taste receptor has been located in the gut, and differences between oral and gut sugar-sensing 
pathways are discussed. 
Summary: Differences in the sweetness transduction cascade, and neuronal signalling may 
result in incretin hormone release upon activation of the sweet taste receptor from some 
sweeteners, but not others. 
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Introduction 
The use of sweeteners and sweetness enhancers is increasing, partly in response to WHO and 
governmental initiatives set-out to reduce sugar consumption. Sweeteners are primarily 
described by whether they are broken down to provide energy or not. The term nutritive 
sweeteners (NS) encompass all sweetening agents that provide energy (as kcal/g), whereas 
non-nutritive sweeteners (NNS) are undigested and therefore provide negligible energy 
content. The NS category can be further broken down into sugars (glucose, fructose, sucrose, 
dextrose) including honey and maple syrup, or polyols – sugar alcohols such as sorbitol, 
mannitol and xylitol – also known as bulk sweeteners. All NS are metabolised by the body, 
however, polyols provide lower energy compared to sugars (1-2 kcal/g and 4 kcal/g, 
respectively) (1). The majority of NNS are artificially synthesized (hence, artificial 
sweetener), however, some are derived from natural sources; steviol glycosides is a natural 
extract from Stevia rebaudiana (2). All of these compounds stimulate oral sweet taste 
perception through activation of the sweet taste receptor; a heterodimer of type 1 taste 
receptor 2 (T1R2)/type 1 taste receptor 3 (T1R3) (3). The T1R2/T1R3 sweet taste receptor is 
expressed not only in the oral cavity but also in several gut cells, indicating a role in gut 
nutrient sensing (3). In this review, recent investigations into the physiological response to 
activation of the T1R2/T1R3 receptor in the oral cavity and gut in response to both sugars and 
sweeteners are summarised and discussed. 
  
The evolved importance of sugar and sweetness 
Human metabolism uses glucose as the primary energy currency; glucose is derived from 
dietary intake upon the digestion and subsequent absorption of complex and simple 
carbohydrates. Plant-derived foods are the richest source of mono- and disaccharides, and 
progressive hydrolysis of complex carbohydrates such as starch, ultimately provides large 
amounts of glucose. Fruits, nuts and berries contain high amounts of simple mono- and 
disaccharides such as glucose, fructose, maltose and sucrose. Digestion of starchy roots and 
tubers, i.e. potatoes, yams, cassava, along with cereals and grains such as wheat, barley, rice 
and millet yield large quantities of glucose. Natural sugars and sweeteners exist in the form of 
honey, maple syrup, carob, and sucrose (table sugar) has been extracted from sugar cane 
(Saccharum officinarum) and sugar beets (Beta vulgaris) since the 18th Century (2). These 
nutritive sweeteners (NS) have been used in food preparation for many years, however, more 
recently, the use of polyols and non-nutritive sweeteners (NNS) has increased (1) . 
 
Humans have consumed sugars throughout evolution, and it is believed that carbohydrates 
were an increasingly important component of hominin diets, since the advent of cooking (4) . 
It has been suggested that cooked carbohydrates and sugars were integral to our evolution and 
survival to support increased energy demands of human’s relatively increased cranial 
capacity(4, 5) . Given the high energy demands of the human brain (20% of total energy 
intake), a mechanism to quickly identify sweet and nutrient-dense foods would have provided 
a survival advantage. This has led to the evolution of complex and discreet nutrient sensing 
pathways both in the oral cavity and the gut. 
 
Despite the necessity for sugar and carbohydrate intake during evolution, evidence suggests 
chronic high sugar consumption in the modern dietary and lifestyle landscape, may contribute 
towards detrimental energy homeostasis(6, 7). Over the past 20 years the UK has experienced 
a dramatic rise in the incidence of type-2 diabetes mellitus (T2DM) and a near parallel 
increase in obesity rates – itself a principal risk factor for T2DM development.  Despite the 
multifactorial risk factors for both T2DM and obesity including hereditary genetic and 
lifestyle components, diet and lifestyle management is pivotal to reducing the incidence of 
type 2 diabetes mellitus (8). 
 
Changes in sugar intake guidelines  
The Scientific Advisory Committee on Nutrition’s review on the role of dietary carbohydrates 
in health (7) , and the 2015 changes to the WHO dietary guidelines (9) , both proposed a 
reduction in sugar consumption. There has been increased focus of healthcare professionals 
and organizations to encourage the public to reduce sugar consumption. Current 
recommendations are that sugar should contribute up to 10% of daily caloric intake; 30g 
adults and 19g children(9) . Potential health benefits of a reduction in sugar intake, include 
the correlated reduction in total energy intake, which may help prevent obesity, and reduce 
risk of dental caries  (7, 10). This has led to increased use of NNS, which provide sweetness 
in the absence of calories, such as polyols, aspartame, sucralose and Ace-K in the food and 
beverage industry, largely due to their associated health benefits. 
   
Oral sweet taste perception, and sugar sensing 
Humans perceive a diverse range of chemical compounds as sweet tasting, including sugars 
(glucose, fructose, sucrose, maltose), polyols (sorbitol, erythritol), artificial sweeteners 
(saccharin, aspartame, cyclamate), sweet amino acids (d-tryptophan, d-phenylalanine, d-
serine), and sweet proteins (monellin, brazzein, thaumatin). NNS approved for use in the EU 
include aspartame, sucralose, saccharin, acesulfame-k (Ace-K), cyclamate, neohesperidin and 
steviol glycosides(2) . All of these ligands stimulate oral sweet taste perception through 
activation of the sweet taste receptor.  
 
The human sweet taste receptor is a transmembrane heterodimer of type-1 taste receptor 2 and 
type-1 taste receptor 3 (T1R2 and T1R3, respectively), known as T1R2/T1R3. Expression of 
TAS1R2 and TAS1R3 genes encoding T1R2 and T1R3 respectively, have been reported in the 
circumvallate papillae and foliate papillae taste receptor cells in the mouth (11) . Both T1R2 
and T1R3 belong to Class C of G protein-coupled receptors (GPCRs), and feature the distinct 
N-terminal Venus flytrap domain (VFT), connected by a short cysteine-rich linker region to 
the seven transmembrane domain, typical of Class C GPCRs (12).   
 
The T1R2 and T1R3 VFT domains carry different binding sites, with different affinities for 
sugars and sweeteners. Glucose, sucrose and sucralose can bind to the VFT domain of both 
T1R2 and T1R3. T1R2 shows broader specificity for natural sugars and NNS, including 
aspartame, whereas cyclamate can activate T13R through binding to the seven 
transmembrane domain, rather than the VFT domain. Furthermore, sweet tasting proteins 
(e.g. thaumatin and monellin), achieve activation through simultaneous binding of regions on 
T1R2 and T1R3 (13). 
 
Ligand-binding of T1R2/T1R3 on the apical surface of taste cells activates the release of G-
protein α-gustducin. However, there is evidence that different pathways can then be triggered 
by natural sugars versus sweeteners. Stimulation of the GCPRs by natural sugars leads to 
adenylate cyclase activation that depolarizes the taste cell, leading to increased cAMP 
concentration, this can then either directly or indirectly close basolateral potassium channels, 
ultimately resulting in neurotransmitter release (13). 
 
 Alternatively, binding from sweeteners leads to phospholipase C β2 activation – rather than 
adenylate cyclase – that produces intracellular release of Ca2+ which in-turn activates the 
transient receptor potential cation channel M5 (TRPM5), resulting in ATP 
release.   Ultimately, binding of sweet taste receptors results in sweet taste perception through 
neurotransmitter release either from direct changes in depolarisation or by second messenger-
mediated changes in intracellular Ca2+ concentration. Currently, it is believed that both 
pathways are triggered from the same taste cell (13). The pathways result in stimulation of 
sensory neurons that send signals to brain centers involved in taste perception and the reward 
centres. It has been suggested that there are separate, yet integrated, neuronal circuits 
involved in taste perception and nutritional value yet it remains largely unknown if oral and 
gut T1R2/T1R3 use the same neural circuitries (14). Currently, the evidence for nutritional 
evaluation of sweetness appears to be a result of gastric glucose availability (14). 
 
Oral perception of sweetness is described by the intensity and duration of sweetness 
experienced, this has been associated to differences in binding patterns to the multiple binding 
sites of T1R2/T1R3 (15).  Often, polyols and NNS are used in varying combinations in order 
to achieve a combined sweetness profile similar to sucrose, whilst providing a healthy, low-
energy burden. Many NNS are considered high-intensity sweeteners as they are many times 
sweeter than sucrose, i.e. saccharin 200-700x, sucralose is 600x sweeter, and aspartame and 
Ace-K are both ~200x. Therefore they are often used at much lower concentrations than 
sucrose to provide equivalent sweetness to food and beverages (1). 
 Sugars, NS and NNS are all perceived as sweet tasting due to their ability to bind to the T1R 
family of sweet taste receptors in the oral cavity. This triggers the sweetness transduction 
cascade, in the case of glucose and other glucose-containing sugars, this elicits a cephalic 
response, however, evidence suggests this response is absent after NNS consumption (16). 
The cephalic response leads to GLP-1 release which prompts sugar transporters to localise, 
stimulates release of insulin, thus promoting glucose clearance from the blood. 
 
Gut sugar-sensing and signalling 
Nearly a decade has passed since the discovery of TAS1R2 and TAS1R3 expression in 
intestinal enterocytes and enteroendocrine cells. There is evidence for the co-localisation of 
T1R2/T1R3 and α-gustducin, in human intestinal epithelium, and that T1R2/T1R3 becomes 
activated in the lumen in the presence of sweet nutrients, much like in the oral cavity (17)**.  
 
A secondary mechanism of luminal glucose-sensing has been proposed in the hormone 
producing enteroendocrine cells of the intestine. Under conditions of luminal glucose 
concentrations >30mM, sodium-dependent glucose co-transporter 1 (SGLT1) increases co-
transportation of glucose and Na+ into the cell, increasing the cells  electrogenicity. This 
generates action potentials and triggers cell membrane depolarization and Ca+2 entry into the 
cell (18). This signalling cascade results in the secretion of numerous gut hormones, including 
the incretin hormones; glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic 
peptide (GIP) (18).  
 
These incretin hormones are vital in reducing blood glucose concentration, through their 
insulinotropic activity. Once secreted they travel and act upon their respective receptors on 
pancreatic beta-cells to stimulate insulin secretion and synthesis (19). GLP-1 is also involved 
in appetite regulation by interacting with its receptors located on the brain and stomach, 
decreasing food intake and increasing satiety, and decreasing gastric emptying, respectively 
(20). Evidence supporting T1R2/T1R3 and α-gustducin’s direct involvement in GIP secretion, 
however is lacking (17)**.  
 
Differences in non-nutritive sweetener sensing 
NNS are thought to interact and activate the sweet taste receptors in the gut as they do in the 
mouth. Sucralose has been shown to be an agonist for T1R2/T1R3 receptors, resulting in 
incretin secretion in vitro, with both mouse and human enteroendocrine cell lines (21) . 
However, the concentration of sucralose used (50mM) is typically much higher than normal 
luminal concentrations (0.04-0.1mM), therefore extrapolation into a relevant physiological 
response is limited.  
 
Using perfused rat small intestines, Saltiel et al. (17)** demonstrated that intra-luminal doses 
of sucralose, stevioside and Ace-K did not elicit GIP secretion, and only Ace-k stimulated 
GLP-1 release. Interestingly, intra-vascular dosing of sucralose and stevioside induced both 
GLP-1 and GIP secretion, while Ace-K did not stimulate any incretin release. These results 
suggest gut sweet taste receptors may be basolaterally located, in which case, sucralose and 
stevioside are unlikely to be capable of eliciting a response in vivo since they do not cross the 
brush-border membrane. However, Ace-k’s ability to induce GLP-1 secretion indicate that 
there may be some apically located receptors. It is possible that GLP-1 secretion may only be 
stimulated through some specific ligand-binding to T1R2/T1R3 -  with certain NNS being 
able to interact with the sweet taste receptors and other unable to, though further research is 
needed to test this hypothesis. 
 
The traditional understanding is that NNS can be used to help lower or control blood glucose 
levels. In vitro and Ex vivo rodent studies provided evidence that NNS may increase glucose 
uptake in intestinal epithelium cells by activating T1R2/T1R3 and α-gustducin which may 
signal another transporter – the GLUT2 transporter – to translocate to the apical membrane 
and up-regulate glucose transport (22). Similarly, pre-incubation of Caco-2 cells with Ace-K 
was reported to promote glucose uptake only in glucose concentrations >25mM , suggesting 
saturation of SGLT1 increased glucose uptake in the presence of Ace-K, via GLUT2 
translocation (22). However, a similar study, pre-incubated cells with Ace-K and sucralose, 
but did not observe significant differences in glucose uptake in concentrations of glucose 
ranging from 2.5mM to 75mM (23). However, a recent report suggested that certain NNS 
may promote glucose transport via incretin secretions leading to increased blood glucose 
concentrations (24)* . 
 
Since 1996, there are almost 20 publications of randomised controlled human trials (RCT) 
investigating the effect of NNS, on postprandial glycaemia and insulinaemia. A recent 
systematic review of observational studies involving / comparing NNS reported no clear 
consensus on the effects of NNS on glucose metabolism(24) *. Clinical trials in humans 
investigating the effects of NNS, including aspartame, sucralose and Ace-K, on gut hormone 
secretion have provided conflicting results. With some studies suggesting aspartame 
decreases GLP-1 secretion, and others suggesting ace-k and sucralose increase secretion (25) . 
A recent trial conducted a 12-week, double-blind parallel study provides concurrent evidence 
indicating sucralose does not affect glycaemic control  (26) **.  The absence of caloric 
burden, in combination with un-altered glucose metabolism makes most NNS and polyol 
sweeteners suitable for individuals with metabolic disorders such as T2DM. 
 
Conclusion 
The evolved redundancy of the sweet taste receptor to become activated by such a wide 
variety of chemical ligands, highlights the importance of sweet-tasting foods. Within an 
evolutionary context, a mechanism to quickly identify sweet and by association, nutrient-
dense foods would have provided a survival advantage. However, in the modern dietary 
landscape, where not all sweet tasting molecules provide caloric energy, it appears the brain - 
via reward centres - and body - via glucose homeostasis - is able to access and respond 
appropriately to caloric vs non-caloric sweeteners.  
 Recent research has focused on laying the foundation of understanding nutrient-sensing 
pathways in the gut via the T1R family of sweet taste receptors. Animal studies, and human in 
vitro research suggests NNS can activate the gut sweet taste receptors, and under some 
conditions elicit incretin hormone release. However, the preponderance of evidence from 
human studies suggest NNS have no effect on glucose metabolism. This highlights the 
importance of understanding differences in the physical binding of the T1R2/T1R3 proteins 
and their subsequent variance in the transduction cascade, and neuronal signalling in 
understanding the differences in physiological response between sugars, NS and NNS.  
 
Key points:  
• The sweet taste receptor, T1R2/T1R3, is found in the oral cavity and throughout the 
intestine and binds both nutritive sweeteners (i.e. glucose, fructose, sucrose) and non-
nutritive sweeteners (i.e. aspartame, acesulfame-k, sucralose). 
• The evidence on whether non-nutritive sweeteners have an impact on incretin 
hormone secretion and glycemia in humans is unclear, with the majority of studies 
reporting no significant effects. 
• The negligible caloric content in non-nutritive sweeteners may be the reason for the 
lack of physiological effect as the T1R2/T1R3 receptors may have evolved in humans 
to distinctly recognize sweet tasting molecules that provide energy.  
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